Objective Traditional Chinese medicine Sheng Xue Bao has been approved for treating iron deficiency anemia in China. This study aimed to collect evidence and quantify the effect of Sheng Xue Bao on IDA.
Methods Seven online databases were surveyed up to July 13, 2021. Randomized controlled trials in which SXBM was combined with conventional therapies to treat iron deficiency anemia and compared with placebo or conventional therapies were included in the study. The red blood cell (RBC) count, hemoglobin (Hb) level, and serum ferritin (SF) level, and adverse events rate (AER) were evaluated.
Results A total of 1108 patients from 8 trials were recruited. Sheng Xue Bao plus conventional therapy increased the Hb level [mean difference (MD) = 13.04, 95% confidence interval (CI) 8.37-17.7, P < 0.00001], RBC count (MD = 0.41, 95% CI 0.19-0.62, P = 0.002), and SF level (MD = 6.25, 95% CI 2.88-9.62, P = 0.0003),and AER [Risk Ratio(RR)=0.56 ,95% CI 0.36-0.86; P = 0.008].
Conclusions Sheng Xue Bao combined with conventional treatment seemed to be beneficial for patients with iron deficiency anemia.